Adipocytokines in primary antiphospholipid syndrome: Potential markers of low-grade inflammation, insulin resistance and metabolic syndrome

Clinical and Experimental Rheumatology

Volumn 30, Issue 6, 2012, Pages 871-878

  Rodrigues, C E M ^a   Vendramini, M B ^a   Bueno, C ^a   Bonfa E ^a   de Carvalho, J F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adipocytokines; Inflammation; Insulin resistance; Metabolic syndrome; Primary antiphospholipid syndrome

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LIPOPROTEIN; LIPOPROTEIN A; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TRIACYLGLYCEROL; URIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

ADIPOKINES; ADIPONECTIN; ADULT; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LEPTIN; LINEAR MODELS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN;

EID: 84871666488     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. DE GROOT PG, DERKSEN RH, DE LAAT B. Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. Semin Thromb Hemost 2008; 34: 347-55.
2. MEDINA G, GUTIÉRREZ-MORENO AL, VERALASTRA O, SAAVEDRA MA, JARÁ LJ. Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev 2011; 10; 214-7.
3. SHOENFELD Y, GERLI R, DORIA A et al.. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-47.
4. MEDINA G, CASAOS D, JARA LJ et al.. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 2003; 62: 607-10.
5. SACRÉ K, BRIHAYE B, HYAFIL F et al.. Asymptomatic myocardial ischemic disease in antiphospholipid syndrome. Arthritis Rheum 2010; 62: 2093-100.
6. MATSUZAWA Y, FUNAHASHI T, KIHARA S, SHIMOMURA I. Adiponectin and metabolic syndrome. Arteriocler Thromb Vasc Biol 2004; 24: 29-33.
7. WHITEHEAD JP, RICHARDS AA, HICKMAN IJ, MACDONALD GA, PRINS JB. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264-80.
8. FANTUZZI G. Adipose tissue, adipokines, and inflammation: J Allergy Clin Immunol 2004; 23: 416-20.
9. DERDEMEZIS CS, VOULGARI PV, DROSOS AA, KIORTSIS DN. Obesity, adipose tissue and rheumatoid arthritis: coincidence or more complex relationship? Clin Exp Rheumatol 2011; 29: 712-27.
10. GUZIK TJ, MANGALAT D, KORBUT R. Adipocytokines - novel link between inflammation and vascular function. J Physiol Pharmacol 2006; 57: 505-28.
11. LAGO F, DIEGUEZ C, GOMEZ-REINO J, GUALILLO O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007; 18: 313-25.
12. CHUNG CP, AVALOS I, OESER A et al.. High prevalence of the metabolic syndrome in patients with systemic lupus erithematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 208-14.
13. MAAHS DM, OGDEN LG, KINNEY GL et al.. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005; 111: 747-53.
14. CHUNG CP, LONG AG, SOLUS JF et al.. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 2009; 18: 799-806.
15. RHO YH, CHUNG CP, SOLUS JF et al.. Adipocytokines, insulin resistance, and coronary atherosclerosis in Rheumatoid Arthritis. Arthritis Rheum 2010; 62: 1259-64.
16. MIYAKIS S, LOCKSHIN M, ATSUMI T, BRANCH D, BREY R, CERVERA R. International concensus statement on an update of the classification for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
17. NATIONAL CHOLESTEROL EDUCATION PROGRAM: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
18. HARIS EN, PIERANGELI S, BIRCH D. Cardiolipin Wet Workshop report. Am J Clin Path 1994, 101: 616-24.
19. WISLOFF F, JACOBSEN EM, LIESTOL S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2002; 108: 263-71.
20. SIEDEL J, HAGELE EO, ZIEGENHORN J, WAHLEFELD AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29: 1075-80.
21. FOSSATI P, PRENCIPE L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28: 2077-80.
22. WARNICK GR, CHEUNG NC, ALBERS JJ. Comparison of current methods for high density lipoprotein cholesterol quantification. Clin Chem 1979; 25: 596-604.
23. FRIEDWALD WT, LEVY RI, FREDRICKSON DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
24. ALBERTI KG, ZIMMET P, SHAW J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.
25. REILLY MP, WOLFE ML, RHODES T, GIRMAN C, MEHTA N, RADER DJ. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004; 110: 803-9.
26. CICERO AF, MAGNI P, LENTINI P et al.. Sex hormones and adipokines in healthy premenopausal, post-menopausal and elderly women, and in age-matched men: data from the Brisighella Heart Study. J Endocrinol Invest 2011; 34: e158-62.
27. SADA KE, YAMASAKI Y, MARUYAMA M et al.. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 2006; 33: 1545-52.
28. DOMALI E, MESSINIS IE. Leptin in pregnancy. J Matern Fetal Neonatal Med 2002; 12: 222-30.
29. RAMSAY JE, JAMIESON N, GREER IA, SATTAR N. Paradoxical elevation in adiponectin concentrations in women with preeclampsia. Hypertension 2003; 42: 891-4.
30. LAUMEN H, SKURK T, HAUNER H. The HMGCoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis 2008; 196: 565-73.
31. KATERA ALA, BATISTA MC, FERREIRA SRG. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism Clinical and Experimental 2010; 59: 921-6.
32. SUN YM, LI J, LUAN Y, WANG LF. Effect of statin therapy on leptin levels in patients with coronary heart disease. Peptides 2010; 31: 1205-7.
33. MIYAZAKI Y, DEFRONZO RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes obes Metab 2008; 10: 1204-11.
34. LAURBERG TB, FRYSSTYK J, ELLINGSEN T et al.. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with arthritis and control. J Rheumatol 2009; 36: 1885-91.
35. MARTIN SS, QASIM A, REILLY MP. Leptin resistance- a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008; 52: 1201-10.
36. DE MITRIO V, DE PERGOLA G, VETTOR R et al.. Plasma plasminogen activator inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women. Metabolism 1999; 48: 960-4.
37. CHU NF, SPIEGELMAN D, HOTAMISLIGIL GS, RIFAI N, STAMPFER M, RIMM EB. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 2001; 157: 495-503.
38. SKURK T, VAN HARMELEN V, LEE YM, WIRTH A, HAUNER H. Relationship between IL-6, leptin and adiponectin and variables of fibrinolysis in overweight and obese hypertensive patients. Horm Metab Res 2002; 34: 659-63.
39. AMES PRJ, ANTINOLFI I, CIAMPA A et al.. Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease? Rheumatology 2008; 47: 1832-37.
40. AMES PRJ, MATSUURA E, BATUCA JR et al.. High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome. Lupus 2010; 19: 711-16.
41. REILLY MP, RADER DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003; 108: 1546-51.
42. LÓPEZ-PEDRERA C, CUADRADO MJ, HERNÁNDEZ V et al.. Proteomic analysis in monocytes of antiphospholipis syndrome patients. Arthritis Rheum 2008; 58: 2853-44.
43. CUGNO M, BORGHI MO, LONATI LM et al. Patients with antiphospholipis syndrome display endothelial pertubation. J Autoimmun 2010; 34: 105-10.
44. GIANNAKOPOULOS B, PASSAM F, RAHGOZAR S, KNILIS AS. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007; 109: 422-30.
45. URBANUS RT, SIEGERINK B, ROEST M, ROSENDAAL FR, DEGROOT PG, ALGRA A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a casecontrol study. Lancet Neurol 2009; 8: 998-1005.
46. RUFFATTI A, DEL ROSS T, CIPRIAN M et al.. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011; 70: 1083-6.
47. AMES PR, ANTINOLFI I, SCENNA G, GAETA G, MARGAGLIONE M, MARGARITA A. Atherosclerosis in thrombotic primary antiphospholipid syndrome. J Thromb Haemost 2009; 7: 537-42.
48. POPA C, NETEA MG, DE GRAAF J et al.. Circulating leptin and adiponectin Concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol 2009; 36: 724-30.
49. SCHALKWIJK CG, STEHOUWER CD. PAI-1 inhibition in obesity and the metabolic syndrome: a promising therapeutic strategy. Thromb Haemost 2006; 96: 698-9.
50. ALESSI MC, JUHAIS-VAGUE I. PAI-1 and the metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 2200-7.